Clinical significance of incidental focal colorectal 18F-fluorodeoxyglucose uptake: Our experience and a review of the literature

Colorectal Disease

Volumn 14, Issue 2, 2012, Pages 174-180

  Treglia, G ^a   Calcagni, M L ^a   Rufini, V ^a   Leccisotti, L ^a   Meduri, G M ^a   Spitilli, M G ^a   Dambra, D P ^a   De Gaetano, A M ^a   Giordano, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

18F fluorodeoxyglucose ( 18F FDG); Colonoscopy; Incidental colorectal lesions; Positron emission tomography computed tomography (PET CT)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER PATIENT; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NEOPLASM; PRECANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; COLONIC NEOPLASMS; COLONIC POLYPS; COLONOSCOPY; DIVERTICULITIS, COLONIC; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENTAL FINDINGS; LEIOMYOSARCOMA; LYMPHOMA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84855744448     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2011.02588.x     Document Type: Article

References (35)

1. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
2. Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA. Bowel hot spots at PET-CT. Radiographics 2007; 27: 145-59.
3. Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med 2001; 28: 1766-9.
4. Zhuang H, Hickeson M, Chacko TK et al. Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin Nucl Med 2002; 27: 628-32.
5. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002; 224: 783-7.
6. Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004; 230: 417-22.
7. Pandit-Taskar N, Schöder H, Gonen M, Larson SM, Yeung HW. Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol 2004; 183: 1143-7.
8. 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004; 45: 1804-10.
9. Gutman F, Alberini JL, Wartski M et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol 2005; 185: 495-500.
10. 18F-FDG uptake: incidence, localization, patterns and clinical significance. J Nucl Med 2005; 46: 758-62.
11. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46: 752-7.
12. Even-Sapir E, Lerman H, Gutman M et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006; 33: 541-52.
13. Wang G, Lau EW, Shakher R et al. How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?. Cancer 2007; 109: 117-24.
14. Hemandas AK, Robson NK, Hickish T, Talbot RW. Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Dis 2008; 10: 386-9.
15. Lee ST, Tan T, Poon AM et al. Role of low-dose, noncontrast computed tomography from integrated positron emission tomography/computed tomography in evaluating incidental 2-deoxy-2-[F-18]fluoro-D-glucose-avid colon lesions. Mol Imaging Biol 2008; 10: 48-53.
16. Beatty JS, Williams HT, Aldridge BA et al. Incidental PET/CT findings in the cancer patient: how should they be managed?. Surgery 2009; 146: 274-81.
17. Lee JC, Hartnett GF, Hughes BG, Ravi Kumar AS. The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. Nucl Med Commun 2009; 30: 333-7.
18. Weston BR, Iyer RB, Qiao W, Lee JH, Bresalier RS, Ross WA. Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center. Cancer 2010; 116: 1454-61.
19. Ozkol V, Alper E, Aydin N, Ozkol HF, Topal NB, Akpinar AT. The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography. Nucl Med Commun 2010; 31: 128-36.
20. Luboldt W, Volker T, Wiedemann B et al. Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off. Eur Radiol 2010; 20: 2274-85.
21. Kei PL, Vikram R, Yeung HW, Stroehlein JR, Macapinlac HA. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol 2010; 194: W401-6.
22. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer: Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-8.
23. Nusko G, Mansmann U, Kirchner T, Hahn EG. Risk related surveillance following colorectal polypectomy. Gut 2002; 51: 424-8.
24. Yasuda S, Ide M, Fujii H et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000; 83: 1607-11.
25. Chen YK, Kao CH, Liao AC, Shen YY, Su CT. Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer Res 2003; 23: 4357-61.
26. Terauchi T, Murano T, Daisaki H et al. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report. Ann Nucl Med 2008; 22: 379-85.
27. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002; 50: 840-4.
28. Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Randomised study of biennal screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004; 39: 846-51.
29. Colombo L, Corti G, Magrì F et al. Results of a pilot study of endoscopic screening of first degree relatives of colorectal cancer patients in Italy. J Epidemiol Community Health 1997; 51: 453-8.
30. Arrigoni A, Sprujevnik T, Alvisi V et al. Clinical identification and long-term surveillance of 22 hereditary non-polyposis colon cancer Italian families. Eur J Gastroenterol Hepatol 2005; 17: 213-9.
31. Cook GJ. Pitfalls in positron emission tomography/computed tomography interpretation. Q J Nucl Med Mol Imaging 2007; 51: 235-43.
32. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19: 61-77.
33. Antoch G, Kuehl H, Kanja J et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004; 230: 879-85.
34. Groves AM, Kajani I, Dickson JC et al. Oral contrast medium in PET/CT: should you or shouldn't you? Eur J Nucl Med Mol Imaging 2005; 32: 1160-6.
35. Hakama M, Coleman MP, Alexe DM, Auvinen A. Cancer screening: evidence and practice in Europe 2008. Eur J Cancer 2008; 44: 1404-13.